Recent Court of Justice of the European Union (CJEU) judgements on the interpretation of supplementary protection certificate (SPC) regulations are not clear and have left judges frustrated, said Huw Evans, a partner at Norton Rose LLP, speaking at the 1st Annual Life Sciences Law Forum in London.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at firstname.lastname@example.org
SPC, CJEU, IPO